X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (301) 301
female (236) 236
index medicus (223) 223
procollagen - blood (214) 214
peptide fragments - blood (193) 193
middle aged (183) 183
male (179) 179
aged (157) 157
biomarkers - blood (157) 157
osteoporosis (144) 144
endocrinology & metabolism (131) 131
adult (127) 127
collagen (124) 124
procollagen (105) 105
collagen type i - blood (96) 96
biochemical markers (94) 94
peptides - blood (94) 94
bone turnover (86) 86
postmenopausal women (83) 83
bone density (80) 80
mineral density (73) 73
bones (72) 72
aged, 80 and over (69) 69
orthopedics (69) 69
biomarkers (68) 68
metabolism (63) 63
bone mineral density (62) 62
osteocalcin - blood (60) 60
density (58) 58
alkaline phosphatase - blood (57) 57
osteocalcin (55) 55
rheumatology (55) 55
women (54) 54
medicine & public health (53) 53
fractures (51) 51
bone density - drug effects (50) 50
bone and bones - metabolism (47) 47
bone remodeling - physiology (47) 47
animals (46) 46
bone turnover markers (46) 46
physiological aspects (43) 43
bone density conservation agents - therapeutic use (42) 42
bone remodeling (42) 42
bone resorption (41) 41
collagen type i (41) 41
endocrinology (41) 41
analysis (39) 39
pinp (39) 39
health aspects (38) 38
turnover (38) 38
alendronate (37) 37
research (37) 37
procollagen - metabolism (36) 36
bone (35) 35
markers (35) 35
osteogenesis (35) 35
peptide fragments - metabolism (35) 35
treatment outcome (34) 34
resorption (33) 33
risk factors (32) 32
vitamin d (32) 32
bone density - physiology (31) 31
bone remodeling - drug effects (31) 31
medical laboratory technology (31) 31
care and treatment (30) 30
parathyroid hormone (30) 30
disease (28) 28
i collagen (28) 28
medicine, research & experimental (28) 28
bone-mineral density (27) 27
collagen - blood (27) 27
postmenopausal osteoporosis (27) 27
teriparatide (27) 27
adolescent (26) 26
biomarkers - metabolism (26) 26
hormone replacement therapy (26) 26
osteoporosis - drug therapy (26) 26
osteoporosis, postmenopausal - drug therapy (26) 26
parathyroid-hormone (26) 26
peptides (26) 26
spine (26) 26
time factors (26) 26
oncology (25) 25
prospective studies (25) 25
research article (25) 25
risk (25) 25
therapy (25) 25
collagen type i - metabolism (24) 24
rats (24) 24
serum (24) 24
follow-up studies (23) 23
iii procollagen (23) 23
medicine (23) 23
reference values (23) 23
bone growth (22) 22
bone markers (22) 22
cross-sectional studies (22) 22
double-blind method (22) 22
elderly-women (22) 22
hip (22) 22
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (368) 368
Japanese (3) 3
Chinese (2) 2
Portuguese (2) 2
French (1) 1
Russian (1) 1
Spanish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Bone and Mineral Research, ISSN 0884-0431, 03/2011, Volume 26, Issue 3, pp. 530 - 537
Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone density, and reduces fracture risk. This study evaluates the... 
PROCOLLAGEN TYPE I N‐TERMINAL PROPEPTIDE (PINP) | DENOSUMAB | BONE ALKALINE PHOSPHTASE (BALP) | C‐TELOPEPTIDE OF TYPE I COLLAGEN (CTX) | TARTRATE‐RESISTANT ACID PHOSPHATASE (TRACP 5b) | OSTEOPOROSIS | BONE TURNOVER MARKERS | osteoporosis | Bone turnover markers | denosumab | tartrate-resistant acid phosphatase (TRACP 5b) | bone alkaline phosphtase (BALP) | C-telopeptide of type I collagen (CTX) | procollagen type I N-terminal propeptide (PINP) | BIOCHEMICAL MARKERS | VERTEBRAL FRACTURE | PHASE-2 | HEALTHY | TARTRATE-RESISTANT ACID PHOSPHATASE (TRACP 5b) | ALENDRONATE | TRIAL | WOMEN | C-TELOPEPTIDE OF TYPE I COLLAGEN (CTX) | MINERAL DENSITY | REDUCTION | ENDOCRINOLOGY & METABOLISM | BMD | PROCOLLAGEN TYPE I N-TERMINAL PROPEPTIDE (PINP) | Collagen Type I - blood | Isoenzymes - blood | Peptides - blood | Humans | Middle Aged | Tartrate-Resistant Acid Phosphatase | Antibodies, Monoclonal - therapeutic use | Reference Values | Bone Remodeling - drug effects | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | RANK Ligand - pharmacology | Peptide Fragments - blood | Statistics, Nonparametric | Aged, 80 and over | Female | Acid Phosphatase - blood | RANK Ligand - therapeutic use | Alkaline Phosphatase - blood | Osteoporosis, Postmenopausal - enzymology | Antibodies, Monoclonal - pharmacology | Bone Density Conservation Agents - therapeutic use | Procollagen - blood | Biomarkers - blood | Denosumab | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Bone Density - drug effects | Osteoporosis, Postmenopausal - blood | Osteoporosis, Postmenopausal - physiopathology | Aged
Journal Article
Journal Article
Journal Article
Scandinavian Journal of Clinical and Laboratory Investigation, ISSN 0036-5513, 02/2018, Volume 78, Issue 1-2, pp. 125 - 130
Introduction: The aim of this study was to evaluate the concentration of interleukin-6 and N-terminal propeptide of procollagen type I and their relationship... 
N-terminal propeptide of procollagen type I | biomarkers | liver cirrhosis | toxic hepatitis | Interleukin-6 | FIBROSIS | MEDICINE, RESEARCH & EXPERIMENTAL | APOPTOSIS | NECROSIS | CIRRHOSIS | ALPHA | EXPRESSION | Index Medicus
Journal Article
Journal Article
Journal Article
Bone, ISSN 8756-3282, 2015, Volume 81, pp. 581 - 592
Abstract Introduction Bone metastasis remains incurable with treatment restricted to palliative care. Cabozantinib (CBZ) is targeted against multiple receptor... 
Orthopedics | Bone microenvironment | Osteoblast | Bone marrow | Osteoclast | Vasculature | SCATTER FACTOR | OSTEOCLASTS | ANGIOGENESIS | TYROSINE KINASE | HEPATOCYTE GROWTH-FACTOR | ENDOCRINOLOGY & METABOLISM | STROMAL CELLS | RECEPTORS | MET | EXPRESSION | Growth Plate - pathology | Bone and Bones - pathology | Bone Neoplasms - secondary | Male | Bone Remodeling - drug effects | Bone and Bones - drug effects | Bone and Bones - metabolism | Growth Plate - drug effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Bone Neoplasms - drug therapy | Bone Marrow - drug effects | Osteoclasts - pathology | Pyridines - administration & dosage | Osteoblasts - drug effects | Mice, Transgenic | Osteoblasts - pathology | Protein Kinase Inhibitors - administration & dosage | Animals | Anilides - administration & dosage | Mice, Nude | Bone Marrow - pathology | Mice | Mice, Inbred BALB C | Cellular Microenvironment - drug effects | Osteoclasts - drug effects | Vascular endothelial growth factor | Analysis | PBS, phosphate buffered saline | VEGF, vascular endothelial growth factor | MET, hepatocyte growth factor receptor | TRAP, tartrate resistant alkaline phosphatase | PINP, procollagen type 1 N-terminal propeptide | VEGFR-2, vascular endothelial growth factor receptor 2 | CBZ, Cabozantinib | GFP Ob+, green fluorescent protein expressing cells of the osteoblastic lineage | RTK, receptor tyrosine kinase | Original Full Length | CTRL, control | HGF, hepatocyte growth factor
Journal Article
Journal of Bone Oncology, ISSN 2212-1374, 2012, Volume 1, Issue 2, pp. 47 - 56
Abstract We have previously shown that repeated sequential administration of doxorubicin, followed 24 h later by zoledronic acid, inhibits tumour growth in... 
Hematology, Oncology and Palliative Medicine | Bone metastasis | Bisphosphonate | Breast cancer | Combination therapy | ONCOLOGY
Journal Article
Journal Article